Gene Query: CDC6

Dataset Description Geneva Score
Homolog-selective degradation as a strategy to probe the function of CDK6 in AML 132.04
Transcriptomic profiles of human foreskin fibroblast cells in response to orf virus 107.07
CDK12 catalytic activity is rate-limiting for RNAPII processivity on core DNA replication genes and G1/S progression (3' RNA) 105.97
Effects of Cardiac Glycosides on RNA Expression in Prostate Cancer LNCaP-abl Cells 71.86
Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer 69.36
Activation of the p53 transcriptional program sensitizes cancer cells to Cdk7 inhibitors 68.96
Differential gene expression tools exhibit substandard performance for long non-coding RNA-sequencing data 65.08
CD95L derived si- and shRNAs and the CD95L mRNA kill cancer cells through an RNAi mechanism by targeting survival genes [siL3.RNAseq.lg] 64.56
Triplet nucleotide repeat-based siRNAs are highly toxic to cancer cells 63.36
RNA-seq of synchronized S phase or G2 phase cells treated with an ATR inhibitor 61.05
RNA-Seq analysis RPE1 cells following exposure to Nutlin-3 to identify target genes of p53 [tpo12] 59.77
Effect of CHKA knockdown on C4-2 cell transcriptome 58.4
The role of PHF19 in promoting H3K27me3 deposition in multiple myeloma (RNA-Seq) 56.2
The role of PHF19 in promoting H3K27me3 deposition in multiple myeloma 56.2
MenSCs inhibit HCC growth through oncogenic pathway suppression via regulating 5-hmC in enhancer elements 50.66
MenSCs inhibit HCC growth through oncogenic pathway suppression via regulating 5-hmC in enhancer elements [RNA-seq] 50.66
COMBINING BET AND MEK INHIBITORS SYNERGISTICALLY TARGETS NRAS MUTANT MELANOMA 47.63
Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes (ALK) 45.92
24hr CA treatment vs. DMSO in HCT116 cells (from 'Identification of CDK8 and CDK19 substrates in human cells using cortistatin A and quantitative phosphoproteomics') 45.81
Supraphysiological Androgens Repress Prostate Cancer Growth and Induce DNA Damage Augmented by PARP Inhibition 45.15
High-throughput RNA sequencing on circular RNA profiles of human pancreatic cancer cell lines and gemcitabine resistant pancreatic cancer cell lines. 44.97
Gene expression analysis of C4-2 cells treated with ACLY inhibitor and Enzalutamide 43.18
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer (BRD4_JQ1_RNA-seq) 40.77
Transcriptome analysis of U87 cells upon LINC00152 knockdown 39.68
LINE-1 elements are derepressed in senescent cells and elicit a chronic Type-I Interferon response 39.38
Identification of Sin3B regulated genes during quiescence 38.98
Transcriptional Profiling of CENPA-Depleted Prostate Cancer Cell Lines 38.03
CENPA-Bound Genes and Transcriptional Profiling of CENPA-Depleted Prostate Cancer Cells 38.03
Transcriptome analysis of BAP1 knockout and restoration 37.93
Expression profiles of restoration of BAP1 in a BAP1 deficient cell line 37.93
mRNA cap methyltransferase, RNMT-RAM, promotes RNA pol II transcription 37.73
AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition 36.87
Next Generation Sequencing Facilitates Quantitative Analysis of HIV-1 Latency in Central Memory T Cells 36.63
Epigenome-wide Effects of Vitamin-D on Bronchial Epithelial Cells using ATAC-Seq and RNA-seq 36.59
Characterization of transcriptomics landscape in HUVEC cells exposed to oxidative stress (Total RNA) 36.49
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. 36.01
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L [RNA-Seq KO] 35.97
A novel lncRNA lncRNA-AK096729 promotes colorectal carcinogenesis and glucose metabolism by stabilizing and specifying the transcription modification pattern of c-Myc 35.95
Dual inhibition of HDMX and HDM2 as a Therapeutic Strategy in Leukemia 35.92
RNA-Seq analysis of 4N and 2N RPE1 cells following polyploid induction via cytokinesis failure or Aurora kinase inhibition [tpo3] 35.1
Development of a selective CDK9 degrader from a multi-targeted CDK inhibitor [RNA-seq] 34.13
Development of a selective CDK9 degrader from a multi-targeted CDK inhibitor 34.13
Campylobacter concisus pathotypes induce distinct global responses in intestinal epithelial cells [BAA] 33.95
The regulartory role of ZCCHC24 in splicing machinery 33.31
Inhibition of SF3B1 by molecules targeting the spliceosome in Rh18 cells 32.76
Gene expression profiling of LNCaP cells following shRNA-mediated knockdown of TMEFF2 and growth in presence and absence of dihydrotestosterone 32.21
Role for citron kinase in prostate cancer growth 31.8
Culture-induced recurrent epigenetic aberrations in human pluripotent stem cells 31.71
Culture-induced recurrent epigenetic aberrations in human pluripotent stem cells [RNA-seq] 31.71
Effect of FGF13 depletion on the H460 cell line 30.78
Paxillin regulates genomic networks in prostate cancer [LNCaP] 30.57
Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of BET inhibitor JQ1 30.27
Hijacking of stress response machinery by oncogenes in acute leukaemia 29.59
Hijacking of stress response machinery by oncogenes in acute leukaemia [RNA-seq] 29.59
Implication of Long noncoding RNAs in the endothelial cell response to hypoxia revealed by RNA-sequencing. 29.03
Cleavage Factor Im as a key regulator of 3’ UTR length 29.0
Primary human trophoblast from term placenta 28.89
Global Gene Expression analysis of CUTLL1 cell lines after treatment with Perhexiline 28.52
Transcriptome analysis of immature and matured human oocytes from patients of young and advanced maternal age 27.94
Single-cell transcriptomics of the human placenta: inferring the cell communication network of the maternal-fetal interface 27.9
Cancerous inhibitor of PP2A (CIP2A) Constrains Th17 Differentiation by Modulating STAT3 Signaling 27.82
mRNA expression profile of A549 cells and MSR-A549 cells with or without JQ1 treatment 27.67
A549 cells and MSR-A549 cells 27.67
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator [RNA-seq] 27.13
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator 27.13
Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection 27.03
Next generation sequencing on knockdown of AC093323.3 in lung cancer cells 27.02
Luminal lncRNAs Regulation by ERα-controlled Enhancers in a Ligand-independent Manner in Breast Cancer Cells 26.95
Hit-and-run' programing of CAR-T cells using mRNA nanocarriers 26.94
NAD+ Analog-sensitive PARPs Reveal a Role for PARP-1 in Transcription Elongation 26.89
The Adenovirus E1A C Terminus Suppresses a Delayed Antiviral Response and Modulates RAS Signaling [RNA-seq] 26.88
The Adenovirus E1A C Terminus Suppresses a Delayed Antiviral Response and Modulates RAS Signaling 26.88
HBEC-shp53-PCHD7 26.68
Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia [RNA-seq] 26.67
Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia 26.67
The impact of pro-inflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes 26.62
The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma 26.53
IL-33 activates tumor stroma to promote intestinal polyposis 26.16
XBP1s Activation Globally Remodels N-Glycan Structure Distribution Patterns 25.95
Transcription control by the ENL YEATS domain in acute leukemia 25.86
Transcription control by the ENL YEATS domain in acute leukemia [RNA-seq] 25.86
Transcriptome Sequencing of Adipose-Derived Mesechymal Stromal Cells 25.85
Glioblastoma stem cells infected by ZIKA virus 25.84
A rare subpopulation of melanoma cells with low expression of metastasis suppressor NME1 has a neural crest-like phenotype and is highly metastatic in vivo 25.81
SUV420H2 knockdown in PANC-1 25.46
H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers [Nalm-6] 25.35
Cell responses to dysregulated VZV-induced cell-cell fusion 25.3
Effect of venetoclax, tedizolid, and combination treatment on gene expression in a venetoclax-resistant AML cell line 25.28
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. 25.13
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. 25.13
Analysis of Th17 gene signature in the presence of CD28 costimulation in human CD4 naïve T cells 25.03
Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation 24.58
ATRX is necessary for cellular senescence and represses HRAS to drive cells from quiescence into senescence [RNA-Seq] 24.46
ATRX is necessary for cellular senescence and represses HRAS to drive cells from quiescence into senescence 24.46
Small molecule targets TMED9, promotes lysosomal degradation to reverse proteinopathy 24.13
Gene induction by the USP6 oncogene in response to interferon 24.13
Depicting early human development and germ cell origin with porcine embryos 23.28
RNA-seq analysis of uveal melanoma cells treated with FR900359 23.21
Gene expression profile of LMSU gastric cancer cell p53 KO and KD 23.08
SOX21 ensures rostral forebrain identity by suppression of WNT8B during neural regionalization of human embryonic stem cells 23.01
Inducible three-factor direct reprogramming to nephron progenitors using piggyBac transposons 22.99
RNA-seq of resting and activated CD4+ T cells +-JQ1 22.84
Appropriately Differentiated ARPE-19 Cells Regain a Native Phenotype and Similar Gene Expression Profile 22.81
Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function 22.81
Low cytosolic folate cycling is a hallmark of U251 glioblastoma cells reprogramming towards pluripotency 22.5
Low cytosolic folate cycling is a hallmark of U251 glioblastoma cells reprogramming towards pluripotency [RNA-seq] 22.5
Epigenetic Therapy Increases Therapeutic Efficacy in Myeloproliferative Neoplasms Through Inhibition of Aberrant Inflammatory Signaling 22.44
An aspartyl protease defines a novel pathway for export of Toxoplasma proteins into the host cell 22.39
Comparison of expression profiles of APP-depleted prostate cancer cells (LNCaP) 22.28
Alu RNA modulates the expression of cell cycle genes in human fibroblasts 22.2
Differential gene expression analysis between proliferating and quiescent human dermal fibroblasts 21.83
Differentially expressed vascular development genes for iPSC-ECs from CDI 21.36
Integrin signaling regulates YAP/TAZ to control skin homeostasis 21.31
The dynamics of cellular response to therapeutic perturbation using multiplexed quantification of the proteome and transcriptome at single-cell resolution 21.26
CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer 21.18
Identification of global regulators of T-helper cell lineage specification 21.06
Identification of global regulators of T-helper cell lineage specification (RNA-Seq) 21.06
Pan-cancer transcriptomic analysis associates long non-coding RNAs with key mutational driver events 21.03
Direct interaction of MYCN and p53 regulate transcriptional responses in neuroblastoma 20.68
Direct interaction of MYCN and p53 regulate transcriptional responses in neuroblastoma [RNA-Seq] 20.68
Transcriptome analysis of H9 hESC derived cerebral organoids 20.65
Genomic analysis of human parthenogenetic haploid ESCs (hPGES), normal human ESCs(H9) and human forskin fibroblast 20.61
mRNA expression data from human parthenogenetic haploid ESCs (hPGES), normal ESCs (H9) and human fibroblast 20.61
STRIPAK directs PP2A activity to promote oncogenic transformation 20.4
Acriflavine inhibits the epithelial-to-mesenchymal transition in vitro in liver and pancreatic cancer cells (part of study on PANC1 cells treated with CoCl2) 20.32
Transcriptomic analysis of effect of oncolytic measles virus (MV) on transformed and non-transformed bone marrow-derived mesenchymal stem cells (MSCs) 20.21
Identification of HOXB13 target genes responsive to BET inhibitors 19.97
Seletive inhibition of CDK9 in DLBCL cell lines 19.91
Expression profile of LNCaP/AR cells with or without HNF4G expression grown for long term in charcoal stripped-serum (CSS) media 19.8
Comprehensive analysis of microRNA expression in regionalized human neural progenitor cells reveals microRNA-10 as a caudalizing factor 19.68
Targeting MTHFD2 in Acute Myeloid Leukemia 19.67
Gene expression analysis of dengue-infected cells 19.57
ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice 19.48
ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice [HCT116_RNA-seq] 19.48
Montelukast counteracts the influenza virus-induced block in unfolded protein stress response and reduces virus multiplication 19.28
Comprehensive analysis of Long non-coding RNA expression in dorsal root ganglion reveals cell type specificity and dysregulation following nerve injury [human iPS] 19.13
Comprehensive analysis of Long non-coding RNA expression in dorsal root ganglion reveals cell type specificity and dysregulation following nerve injury 19.13
TNF response in promyelocytic and granulocytic forms of HL60/S4 cells 19.06
RNA-seq of human foreskin fibroblast cells lacking RB, p130, and p107 treated with doxorubicin. 18.96
Downregulation of DDX5/DDX17 and REST 18.9
Small-molecule targeting of brachyury transcription factor addiction in chordoma 18.81
Transcriptome of iPSC-derived Neural Cells with Heterozygous Knockout in CHD8 18.79
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging 18.59
Transcriptomic analysis of cultured corneal endothelial cells as a validation for their use in cell-replacement therapy 18.57
The effects of U1 snRNA mutation in chronic lymphocytic leukemia cell lines 18.36
A SIRT1-centered Circuitry Regulates Breast Cancer Stemness and Metastasis 18.3
In vitro differentiation of human low threshold mechanoreceptive (LTMR) neurons from embryonic stem cells 18.27
Crizotinib v. DMSO in SW480 cells 18.24
ROR-γ drives androgen-receptor expression and represents a therapeutic target in castration-resistant prostate cancer 18.2
The ALK downregulated target gene HBP1 and repressor of MYCN activity as synergistic target for combined PI3K/HDAC inhibition 18.1
The ALK downregulated target gene HBP1 and repressor of MYCN activity as synergistic target for combined PI3K/HDAC inhibition [RNA-Seq] 18.1
Gene expression in PANC1 cells treated with Rakicidin 18.09
The p30 isoform of CEBPA uncovers a silent enhancer to drive the expression of the tumor promotive factor CD73 in CEBPA mutant AML 18.05
Large-scale expansion of human iPSC-derived skeletal muscle cells for disease modeling and cell-based therapeutic strategies 17.88
RNA-seq of shEZH2 cells 17.86
Gene expression changes caused by KRAS in MCF-10A 17.8
Gene expression analysis of immortalized human liver progenitor-like cells in culture 17.73
Genome wide expression change by RNF168 knocking down in MCF-7 cells 17.61
Role of BET proteins in YAP/TAZ-dependent transcription [RNA-seq 1] 17.5
RNA-sequencing of human mammary epithelial cells (HMLEs) engineered to express either ER or ER-SOX4 with and without 4-OHT to induce nuclear translocation 17.41
JQ1 +/- Vemurafenib in BRAF mutant melanoma (A375) 17.31
shRNA knockdown of YAP1 in HCC364 cells, various drug conditions 17.26
LncRNA-GAS5 negative regulation of YAP-target genes expression 17.23
MCF10A H-Ras RNA-Seq 17.16
DHX36 resolves G-rich structures in mRNA untranslated region to allow their translation [ChrRNA-seq] 17.15
Transcriptome profiling of hnRNP A2/B1 and A1 depleted cells 17.1
Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade 17.06
Gene expression by high-throughput sequencing of T47D-MTVL human breast cancer cells upon H1.4 knock-down and multiple H1 variants 17.04
Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer 17.0
AhR activity directs BRAF inhibitors resistance in metastastic melanoma 16.76
Spliceosomal disruption of the non-canonical BAF complex in cancer 16.69
A Novel PI3K Regulator, ARID4B, Presents Synthetic Essentiality in PTEN-deficient Prostate Cancer [RNA-seq] 16.58
A Novel PI3K Regulator, ARID4B, Presents Synthetic Essentiality in PTEN-deficient Prostate Cancer 16.58
The effect of Abl kinases,or Ponatinib challenging on breast cancer cells' global transcriptome 16.51
CDK12 catalytic activity is rate-limiting for RNAPII processivity on core DNA replication genes and G1/S progression (nuclear RNA) 16.38
Gene expression profiling of leukemia cells following asparagine depletion 16.37
The landscape of alternative splicing in aggressive prostate cancers 16.36
Synergy from Gene Expression and Network Mining (SynGeNet) method predicts genotype-specific synergistic drug combinations in melanoma 16.31
Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly-dividing de-differentiated state 16.23
Alternative splicing of differentiated myeloid cell transcripts after infection by Anaplasma phagocytophilum impacts a selective group of cellular programs 16.18
Estrogen deprivation triggers and immunosuppressive phenotype in breast cancer cells 16.14
ncRNA (non-coding RNA) signature in endothelial cells during hypoxia 16.11
ncRNA (non-coding RNA) signature in endothelial cells during hypoxia [RNA-seq] 16.11
RNA-sequencing of human vascular endothelial cells after si-RNA mediated gene silencing of interleukin-6 (IL6) 15.99
Ex-vivo Human Hematopoietic Stem Cell Expansion Requires Coordination of Cellular Reprogramming with Mitochondrial Remodeling and P53 Activation [bulk] 15.94
Identifying ASCL1 target genes in primary GBM stem cell cultures [RNA-seq] 15.9
Modeling human brain evolution using induced pluripotent stem cells: comparative analysis of neuronal development in humans and chimpanzees 15.88
FBXW7 modulates stress response by post-translational modification of HSF1 15.82
Transriptional profiling upon heat shock and recovery in cells deficient for FBXW7 and their wild type counterpart. 15.82
UBL5 is essential for pre-mRNA splicing and sister chromatid cohesion in human cells 15.81
To investigate the decay constants (half-lives) of transcript isoforms generated by alternative polyadenylation in proliferating and quiescent cells 15.81
RNA-Seq Analysis of Anacardic Acid Treated MCF7 and MDA-MB-231 Breast Cancer Cell Lines 15.77
RNA-Seq to assess the transcriptional effects of G quadruplex stabilization by the G4 ligand PhenDC3 in HT-1080 cells 15.75
Comparative analysis of mesenchymal stem cells derived from amniotic membrane, umbilical cord and chorionic plate under serum-free condition 15.68
Identification of global XBP1s target gene expression in human prostate cancer cells 15.67
RNA-seq of H1299 cells in which either PRKCI or SOX2 was silenced by validated lentiviral shRNA constructs 15.57
Global transcriptional changes in U87MG glioblastoma cells upon shRNA-mediated TRIM52 knockdown 15.47
scRNASeq analysis of cycling cardiomyocytes 15.45
The Promyelocytic Leukemia Zinc Finger Dependent Transcriptome during Human Endometrial Stromal Cell Decidualization 15.44
Co-transcriptional loading of RNA export factors shapes the human transcriptome 15.42
RNAseq of HEK293 cells after Chtop knockdown 15.42
Overexpression and knockdown experiment for circCSNK1G3 15.31
Transcriptomic analysis of trametinib-resistant HCT116 colorectal carcinoma cells compared to the parental control cells 15.3
Identification of transcription start sites for human A549 cell line using ReCappable-seq 15.28
HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma 15.28
RNAseq of PRMT4KD in human cord blood derived CD34+ cells 15.24
Genome wide mapping of polyadenylation sites in proliferating and contact-inhibited cells and cells with knockdown of cleavage and polyadenylation factors 15.2
Expression profile of HNF1A knockdown and overexpression in 22RV1 and LNCaP cells respectively 15.14
FOXD3 is a novel tumor suppressor in lung cancer 15.14
Safeguarding nucleolar homeostasis by CBX4 alleviates senescence and osteoarthritis 15.1
RNA-seq of UGP2 mutant human embryonic stem cells and in vitro differentiated neural stem cells 15.09
Transcriptomic analysis reveals novel long non-coding RNAs critical for vertebrate development [RNA-Seq] 15.09
Transcriptomic analysis reveals novel long non-coding RNAs critical for vertebrate development 15.09
SETDB1 compacts the inactive X chromosome in part through silencing an enhancer in the IL1RAPL1 gene 14.99
Small-molecule targeting of brachyury transcription factor addiction in chordoma [rnaseq_sgrna] 14.98
DHX36 resolves G-rich structures in mRNA untranslated region to allow their translation [cPDS-RNA-seq] 14.97
Transcriptome analysis of A549 cells expressing a SUMOylation-deficient TRIM28 mutant in the context of influenza A virus infection 14.93
Mining the stiffness-sensitive transcriptome in human vascular smooth muscle cells identifies long non-coding RNA stiffness regulators 14.92
Gene expression profiling by RNA-seq of SW480 TGM2 knockdown cells 14.86
3D genome of multiple myeloma reveals spatial genome disorganization associated with copy number variations 14.8
RNA-seq analysis of RALD iPSCs after in vitro differentiation 14.8
Quantitative Analysis of p53 and/or TGFBR2 Knockdown Endothelial Transcriptomes after Irradiation 14.76
PRMT5 Interacts with the BCL6 Oncoprotein and is Required for Germinal Center Formation and Lymphoma Cell Survival 14.68
mRNA gene expression profiling in a human AML cell line treated with small molecule inhibitors that impact different RNA polymerase transcription complexes, or their combination, in comparison to a global DNA-damaging anthracycline compound 14.58
PHF20 readers link methylation of histone H3K4 and p53 with H4K16 acetylation 14.58
Elongation Factor TFIIS Prevents Transcription Stress and R-Loop Accumulation to Maintain Genome Stability [ RNA-seq] 14.57
Elongation Factor TFIIS Prevents Transcription Stress and R-Loop Accumulation to Maintain Genome Stability 14.57
Small-molecule-based Human Genome G4 Profiling Reveals Potential Gene Regulation Activity 14.48
Combinatorial Reprogramming of Estrogen Signaling by the Nuclear Receptor Family 3C 14.47
Splicing towards noncoding isoforms in colorectal carcinoma is associated with tumor hypoxia and the DNA damage response 14.44
Genome wide transcriptome analysis of palbociclib or GSK3326595 treated A375 cells [Palbociclib_GSK_RNASeq] 14.41
Studying the selectivity of a small molecule Synucleozid on transcriptome 14.36
Nudt3 is a mRNA Decapping Enzyme That Modulates Cell Migration 14.33
RNA-seq differential expression studies: more sequence, or more replication? 14.31
Click chemistry enables comprehensive preclinical evaluation of targeted epigenetic therapies [RNA-seq] 14.29
Click chemistry enables comprehensive preclinical evaluation of targeted epigenetic therapies 14.29
Enriched retinal ganglion cells derived from human embryonic stem cells (RNA-seq) 14.25
A Unique Epigenomic Landscape Defines Human Erythropoiesis 14.13
A Unique Epigenomic Landscape Defines Human Erythropoiesis (RNA-seq) 14.13
Risk SNPs mediated promoter-enhancer switching promotes prostate cancer progression through lncRNA PCAT19 14.11
Risk SNPs mediated promoter-enhancer switching promotes prostate cancer progression through lncRNA PCAT19 (RNA-seq data sets) 14.11
Reprogramming of human stem cells towards a rejuvenated and transformation-resisting state by recoding a single nucleotide 14.0
Cell differentiation grade determines distinct FOXA2 contributions to the cis-regulatory networks of pancreatic cancer cells [RNA-seq] 13.98
Cell differentiation grade determines distinct FOXA2 contributions to the cis-regulatory networks of pancreatic cancer cells 13.98
PolyA-sequencing in IMR-32 cells treated with THZ531 or DMSO 13.98
The lung-enriched p53 mutants V157F and R158L/P regulate a novel transcriptome in lung cancer 13.85
Modeling Trilateral Retinoblastoma using Human Embryonic Stem Cells 13.82
Activation of neuronal genes via LINE-1 elements upon global DNA demethylation in human neural progenitors 13.81
Transcriptome analysis upon C6orf203 silencing 13.81
A TGFbeta-PRMT5-MEP50 Axis Regulates Cancer Cell Invasion through Histone H3 and H4 Arginine Methylation Coupled Transcriptional Activation and Repression 13.71
Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1 13.7
TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation 13.69
BACH2 in human plasma cell fate decision 13.66
Genome-wide transcriptional response to random aneuploidy in human cells 13.6
ER proteostasis and temperature differentially impact the mutational tolerance of influenza hemagglutinin 13.57
Steroid Receptor Coactivator-2 Regulated Transcriptome in Human Endometrial Stromal Cells 13.54
SIRT6 regulates redox homeostasis in human mesenchymal stem cells by the transactivation of NRF2 13.42
DAOY-NERT2 Notch/Hypoxia Transcriptome Analysis 13.37
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma 13.36
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma (RNA-Seq) 13.36
Expression data from A2780 cells treated with DMSO, Olaparib(Ola), Palbociclib(PD), and their combination (Ola/PD) 13.32
RNA-seq analysis of human cardiosphere cells with different tubule supportive potential 13.31
Effect of Influenza virus infection on lncRNA expression in A549 cells 13.3
Osteogenic programming of adipose-derived mesenchymal stem cells using a fungal metabolite that suppresses the Polycomb protein EZH2 13.27
PolyA-sequencing in Kelly and Kelly E9R neuroblastoma cells treated with THZ531 or DMSO 13.21
Examining serotonergic neuron differentiation from human iPSCs 13.2
Global transcriptional profiling changes upon knockdown of LKB1 in human glioblastoma cell lines 13.16
GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance 13.11
MiR-CLIP capture of a miRNA targetome uncovers a lincRNA H19-miR-106a interaction 13.09
Polyol pathway links glucose metabolism to the aggressiveness of cancer cells 13.08
Transcriptome analysis of genetically matched human induced pluripotent stem cells disomic or trisomic for chromosome 21 13.06
Neurotrophic Tyrosine Kinase Receptor 1 is Epigenetically Regulated by IL-13 and Contributes to Allergic Inflammation 13.03
Differential expression analysis of RNA-seq data from melanocytes driven by tumor cell-derived exosomes 13.02
Gene expression analysis of human CD8+ T cells treated with a DOT1L inhibitor 12.98
Overexpression of UGT2B17 in MEC1 and JVM2 leukemia cell lines 12.97
RNA-Seq of polysome profiling fractions and whole cell lysates of UVB-irradiated N-TERT keratinocytes 12.78
Global analysis of alternative splicing regulated by RBM10 12.76
Reconstitution of the human pancreatic niche stimulates differentiation of hESCs into beta cells and reveals new signals for pancreatic endocrine cell maturation 12.67
Characterization of human CDK12 and CDK13 in the regulation of RNA processing 12.53
Total RNA-seq in ALL-SIL upon JQ1 inhibition 12.49
Network-based, cross-cohort discovery of transcriptional mechanisms presiding over maintenance of high-risk neuroblastoma subtype state 12.48
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance [RNA-seq] 12.44
Contribution of SRF and Nkx2-5 to androgen-dependent gene expression in prostate cancer 12.44
Gene expression changes after depletion of Cyclin F and atypical E2Fs in HeLa cells. 12.35
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and are Targetable by BET Bromodomain Inhibition [RNA-seq] 12.32
Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and are Targetable by BET Bromodomain Inhibition 12.32
High-efficiency RNA-based reprogramming of human primary fibroblasts 12.29
ARID1A and ARID1B loss in HCT116 cells 12.26
BRG1 governs Glucocorticoid Receptor interactions with chromatin and pioneer factors across the genome 12.2
Lyophilized human cells stored at room temperature preserve multiple RNA species at excellent quality for RNA sequencing 12.19
mRNA expression in iPS cells generated by a synthetic self-replicative RNA 12.16
Transcriptomic Reprogramming of Prostate Cancer Cells Driven by Stroma-Derived SPINK1 12.13
Genes altered in expression by Cisplatin treatment in lung cancer cell lines 12.12
Inhibition of TAZ contributes radiation-induced senescence and growth arrest in glioma cells 12.02
Transcriptomic alterations in fibroblasts from Parkinson's disease patients carrying Parkin mutations 11.96
Chronic cadmium exposure decreases the dependency of MCF7 breast cancer cells on ERα 11.91
Next-generation RNA sequencing to determine changes in gene expression during breast cancer progression 11.89
RNA expression profiling of human mPB or CB-derived CD34+ cells treated with UM171 at different doses 11.68
RNA Sequencing of default, melanocyte biased and enteric human neural crest populations (NC) and neuroectoderm (CNS) 11.63
Impact of library preparation on downstream analysis and interpretation of RNA-seq data: comparison between Illumina PolyA and NuGEN Ovation protocol 11.55
Effect of Polybrominated diphenyl ethers (PBDEs) on gene expression of MCF7 cells 11.54
Histone H3 lysine 4 acetylation-methylation dynamics define breast cancer subtypes [RNA-seq] 11.52
Histone H3 Lysine4 Acetylation-Methylation Dynamics Define Breast Cancer Subtypes 11.52
RNA-sequencing transcriptome profiling of normal human keratinocytes differentiation 11.4
CASZ1 directly regulates expression of myogenic genes through regional epigenetic modifications to induce muscle and rhabdomyosarcoma cell differentiation 11.4
A map of gene expression in neutrophil-like cell lines 11.31
Integrated analyses of early responses to radiation in glioblastoma identify new alterations in RNA processing and candidate targets to improve treatment outcomes 11.14
The NORAD lncRNA assembles a topoisomerase complex critical for genome stability [RNA-seq] 11.09
The NORAD lncRNA assembles a topoisomerase complex critical for genome stability 11.09
Genome models integrating chromatin contacts and nuclear lamin-genome interactions reveal implications of laminopathy-causing lamin mutations on genome architecture 11.08
Exploiting Prmt5-orchestrated intron detention signatures to treat splicing-addicted malignant glioma tumors 11.04
Transcriptome analysis of human immortilized astrocytes reprogrammed into dopaminergic neurons 10.99
Gene expression profiling associated with knockdown of RNF20 in human normal and malignant lung epithelial cell lines 10.99
Genome-wide transcriptome analysis of organotypic rafts derived from human papillomavirus type 16 infected primary keratinocytes [3D raft] 10.92
The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin Remodeling Complexes 10.9
mRNA sequencing of clinical-grade neural stem cells derived from human ES cells 10.84
Next Generation Sequencing Facilitated Differential Transcriptome Study of melanoma cells transduced with Notch 1 Intracellular Domain (NICD) 10.7
The mechanism of HHT in treating acute myeloid leukemia on RNA level. 10.64
4sU-seq of HFF exposed to salt and heat stress 10.55
RNAseq Study in CC-671 Treated Cal-51 Cells 10.52
BRD9 defines a novel SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors [RNA-seq 2] 10.46
Functional interactions between Mi-2β and AP1 complexes control response and recovery from barrier disruption 10.39
The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis 10.38
Distinct gene expression profile of Huh7 cell lines stably overexpressing CRABP1 or 2 10.36
Analysis of transcriptome changes following SOX2 knockdown in three different Ewing sarcoma cell lines 10.35
Transcriptome profiling of the interconnection of pathways involved in malignant transformation and response to hypoxia 10.26
Cis-SAGe fusion RNAs in transcription splicing factors knocking-down 293T cells 10.25
Transcriptome-wide identification of CELF2 functional targets in T cells 10.16
Cerebral Organoids Recapitulate Epigenomic Signatures of the Human Fetal Brain 10.15
In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide Metformin. 10.12
A code of mono-phosphorylation modulates the function of RB. 10.0
Gene expression profiling by RNA-seq in hTert-HME1 cell line treated with control or BRCA2 siRNAs and grown with or without EGF (epithelial growth factor) 9.99
Knockout of miR-221 and miR-222 reveals overlapping and specific function between paralogous miRNAs 9.82
Gene expression profile of multiple myeloma cell lines treated with CB-5083 9.82
Transcriptional profile in dermal fibroblasts from patients with collagen VI related muscular dystrophy 9.79
JUNB is a critical AP1 component for SMAD2/3 binding after TGFβ stimulation [RNA-seq] 9.75
SMAD2/3 are redirected to novel sites in MCF10A MII after prolonged TGFβ stimulation 9.75
Adenovirus Small E1A Employs the Lysine Acetylases p300/CBP and Tumor Suppressor Rb to Repress Select Host Genes and Promote Productive Virus Infection [RNA-seq] 9.75
Adenovirus Small E1A Employs the Lysine Acetylases p300/CBP and Tumor Suppressor Rb to Repress Select Host Genes and Promote Productive Virus Infection 9.75
Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures [RNA-seq] 9.72
Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures 9.72
Analysis of HPV16 E2 host gene expression using TERT immortalized keratinocytes (NOKs) cell lines and RNA-sequencing 9.61
Identification of a unique subtype of lung squamous cell carcinoma defined by SOX2 and a neural differentiation factor BRN2 [RNA-seq] 9.6
Identification of a unique subtype of lung squamous cell carcinoma defined by SOX2 and a neural differentiation factor BRN2 9.6
RNA-seq transcriptonal profiling in human K562 cells with or without dCas9 and sgRNAs 9.52
In situ CAPTURE of chromatin interactions by biotinylated dCas9 9.52
Global loss of epigenetic and transcriptional fidility defines a subclass of cancer with immunotherapy resistance 9.42
Gene expression profiling in lung and breast cancer cells treated by Bloom-specific siRNAs 9.35
Activation of Wnt/beta-catenin in Ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states 9.32
Cell cycle positioning drives heterogeneity within the pluripotent stem cell compartment 9.29
Systematic Functional Perturbations Uncover a Prognostic Genetic Network Driving Human Breast Cancer [RNA-Seq] 9.04
Systematic Functional Perturbations Uncover a Prognostic Genetic Network Driving Human Breast Cancer 9.04
Poly(A)-specific ribonuclease (PARN) mediates 3' end maturation of the telomerase RNA component 9.0
Insulin induced alterations in chromatin acetylation and transcriptome in triple negative breast cancer cells 8.81
Oxaliplatin resistance is enhanced by saracatinib via upregulation of ABCG1 and Wnt/β-catenin signaling in hepatocellular carcinoma 8.78
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer 8.76
FOXP2's impact on the primate transcriptome 8.73
RNA-seq of three Ewing sarcoma cell lines (A673, SK-N-MC, RDES), transfected with either siControl or siMYBL2. 8.71
Cooperation of dominant oncogenes with regulatory variants shapes clinical outcomes in pediatric cancer 8.71
The ZZ-type zinc finger of ZZZ3 modulates the ATAC complex-mediated histone acetylation and gene activation 8.64
6mer seed toxicity in tumour suppressive microRNAs 8.46
Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid 8.45
Iron response of HepG2 cells 8.43
Biological effect of chronic mistranslation in mammalian cells 8.28
Epithelial-mesenchymal transition markers screenedina cell-based model and validated in lung adenocarcinoma 8.25
Epigenetic siRNA and chemical screens identify SETD8 inhibition as a new therapeutic strategy of p53 reactivation in high-risk Neuroblastoma. 8.15
siRNA-mediated silencing of ORAI3 in MDA-MB-468 breast cancer cells exposed to hypoxia 8.08
Expression changes in MAPKi resistant M229 melanoma lines co-cultured with PD-1 overexpressing HEK293T cells [CellLine.FPKM.batch5] 8.02
Transcriptomic Analysis Of circRNAs/miRNAs/mRNAs upon Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection 7.91
Comparative whole-transcriptomic analysis between normal and AKAP-Lbc-depleted human embryonic stem cells 7.8
Mesenchymal stem/stromal cell engulfment reveals metastatic advantage in breast cancer 7.78
Gene Expression of Breast Cancer Cell Lines Across Biomaterial Platforms 7.71
Loss of CREBBP results in H3K27Ac loss at enhancers and gene expression repression in lymphoma cells 7.69
Loss of CREBBP results in gene expression repression in lymphoma cells 7.69
Derivation and differentiation of haploid human embryonic stem cells [RNA-Seq 1] 7.68
Long non-coding RNA TYKRIL controls pericyte function and survival in the cardiovascular and central nervous system through regulation of p53 activity and PDGFRß expression 7.57
Ro60-knockout cells 7.28
Effect of from Human Umbilical Vein Endothelial Cells 7.25
Global transcriptional changes in the JJN3 myeloma cell line that occur as a result of treatment with 2 pyrrolobenzodiazepine (PBD) monomers 7.24
MARS Seq data from human cortical organoids 7.16
Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice (human RNA-Seq) 7.12
Role of BET proteins in YAP/TAZ-dependent transcription [RNA-seq 2] 7.05
Characterisation of the EZH2 regulated transcriptome in de novo transformed cells (RNA-Seq) 7.03
Characterization of Type I Interferon pathway during Hepatic Differentiation of Human Pluripotent Stem Cells and hepatitis C virus infection 6.97
RNA-seq transcriptonal profiling in human primary adult erythroid progenitor cells (ProEs) after shRNA-mediated depletion of TFAM and PHB2 expression 6.92
β-Caryophyllene Enhances the Transcriptional Upregulation of SREBP-dependent Lipid Biosynthesis in Breast Cancer Cells 6.89
The hepatitis C viral protein NS5A stabilizes growth-regulatory human transcripts 6.88
Metastasis in triple negative breast cancer is dependent on ΔNp63/CXCL2/CCL22-mediated recruitment of myeloid-derived suppressor cells 6.78
Targeting the androgen receptor N-terminus via the cochaperone Bag-1L 6.74
Stochastic genome - nuclear lamina contacts are linked to histone H3K9 dimethylation (RNA-seq data) 6.73
Stochastic genome - nuclear lamina contacts are linked to histone H3K9 dimethylation 6.73
single cell RNA-seq from GM12878 (ENCSR673UIY) 6.71
Distinct structural classes of activating FOXA1 alterations in prostate cancer progression 6.63
Distinct structural classes of activating FOXA1 alterations in prostate cancer progression [RNA-Seq] 6.63
Defective transcription elongation in a subset of cancers confers immunotherapy resistance (human cell lines RNA-Seq) 6.63
Derivation and differentiation of haploid human embryonic stem cells 6.58
LIN28A modulates splicing and gene expression programs in breast cancer cells [RNA-Seq] 6.57
LIN28A modulates splicing and gene expression programs in breast cancer cells 6.57
RNA-sequencing of mRNAs from control and CAP-D3 deficient Salmonella infected HT-29 cells 6.57
PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naïve ESCs 6.22
Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) 6.2
CRISPR-Cas9 based screen for p53-bound enhancers that function in oncogene-induced senescence 6.09
HDAC and NFκB antagonists synergistically inhibit growth and metastatic dissemination of MYC-driven medulloblastoma 5.97
BET-Bromodomain Inhibitors Engage The Host Immune System And Regulate Expression Of The Immune Checkpoint Ligand PD-L1 5.9
BET-Bromodomain Inhibitors Engage The Host Immune System And Regulate Expression Of The Immune Checkpoint Ligand PD-L1 [3mRNA-seq] 5.9
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer 5.79
Transcriptomic analysis of cultured isogenic myotonic dystrophy type 1 myoblasts with and without the DMPK CTG repeat 5.76
INO80 governs super-enhancer-mediated oncogenic transcription and tumor growth in melanoma 5.65
INO80 governs super-enhancer-mediated oncogenic transcription and tumor growth in melanoma [RNA-seq] 5.65
The Genetic Landscape of Diamond-Blackfan Anemia 5.59
Repression of stress-induced LINE-1 expression protects cancer cell populations from lethal drug-exposures 5.46
Repression of stress-induced LINE-1 expression protects cancer cell populations from lethal drug-exposures [RNA-Seq] 5.46
Genomic expression analysis of K562 cells expressing shRNA targeting lncRNA-IIRX and control cells 5.46
Modeling genome-wide transcriptional cis-regulation in n LNCaP-abl cell line after siRNA knock down of a series of gene factors [RNA-seq] 5.44
Distinct Pathological Signatures in Human Cellular Models of Myotonic Dystrophy Subtypes 5.42
High-throughput RNAi cell viability screen to identify selective targets for EWS-FLI1 positive Ewing sarcoma 5.38
SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis 5.34
SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis [Quant-Seq] 5.34
Integration of genome-wide DNA methylome and transcriptome of human intestinal fibroblasts reveals novel candidate gene signatures in Crohn’s disease-associated fibrosis 5.32
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair 5.31
Lung adenocarcinoma metastasis is suppressed by the alveolar lineage transcription factors GATA6 and HOPX. 5.26
Transcriptome analysis on TDP43 and SRSF3 downstream genes and binding RNAs in MDA-MB231 cells by Next Generation Sequencing 5.02
Developing a Novel Two-Dimensional Culture System to Enrich Human Prostate Luminal Progenitors That Can Function as a Cell of Origin for Prostate Cancer 4.95
Neurofibromin is an Estrogen Receptor alpha Transcriptional Co-repressor in Breast cancer 4.93
G9a-Mediated Methylation of ERα Links the PHF20/MOF Histone Acetyltransferase Complex to Hormonal Gene Expression 4.87
Oncogenic Antisense LncRNA P14AS Regulates Expression of ANRIL through AUF1 Binding 4.86
Role of SUMOylation in differential ERα transcriptional repression by SERMs and pure antiestrogens in breast cancer cells 4.83
Analysis of human ES cell differentiation establishes that the dominant isoforms of the lncRNAs RMST and FIRRE are circular 4.45
Transcriptomic analysis of iPSC and ESC challenged with atmospheric or physiological oxygen 4.41
Hyper-activation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2 4.29
Antioxidant metabolism in activated CD8+ T cells regulates stem-like human memory T cell formation and anti-tumor immunity 4.11
The cohesin release factor WAPL restricts chromatin loop extension. 4.02
The cohesin release factor WAPL restricts chromatin loop extension. [RNA-Seq] 4.02
Single-cell RNAseq analysis of the empty and i8TF cell lines after 3 days of BL-CFC culture 4.01
Single cell transcriptomics reveals new insights on the dynamical function of transcription factors during blood stem and progenitor cell formation 4.01
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity 3.91
Mutational landscape of aggressive natural killer-cell leukemia and drug profiling highlight JAK-STAT signaling as a therapeutic target in NK-cell malignancies 3.89
RNA:DNA hybrids in the human genome have distinctive nucleotide characteristics, chromatin composition, and transcriptional relationships 3.83
RNA:DNA hybrids in the human genome have distinctive nucleotide characteristics, chromatin composition, and transcriptional relationships (RNA-seq) 3.83
Human-specific gene ARHGAP11B promotes basal progenitor amplification and neocortex expansion 3.81
Campylobacter concisus pathotypes induce distinct global responses in intestinal epithelial cells 3.77
O-GlcNAc transferase fine-tunes MYC-dependent transcription to promote cell cycle [RNA-seq] 3.74
O-GlcNAc transferase fine-tunes MYC-dependent transcription to promote cell cycle 3.74
Characterization of parental and rociletinib-resistant derived H1975 cell lines 3.68
Expression profiling by RNA-Seq of breast cancer samples from patients in walnut-consuming and control groups 3.67
DRB/GRO-Seq -/+ UV 3.28
Mechanism suppressing H3K9 trimethylation in pluripotent stem cells and its demise by polyQ-expanded huntingtin mutations [RNA-seq] 3.22
Mechanism suppressing H3K9 trimethylation in pluripotent stem cells and its demise by polyQ-expanded huntingtin mutations 3.22
RelA mutants 'reconstituted' and cell cycle synchronized HCT116 Colorectal Cancer Cells 3.19
Analysis of gene expression in primary human foreskin keratinocytes +/- HPV16 E7 or PTPN14 knockout 2.92
MicroRNA-28 replacement for non-Hodgkin lymphoma therapy 2.91
RNA-seq analysis of PRMT5-regulated genes in irradiated/non-irradiated LNCaP cells 2.87
RNA-Seq analysis of prostate cancer cell line LNCaP treated with vehicle, androgen, androgen and IMTPPE, androgen and JJ-(+)-450, androgen and JJ-(-)450, androgen and enzalutamide 2.8
6mer seed toxicity in viral microRNAs 2.74
RNASeq of MV4;11 cell treated with DMSO, I-BET, SGC0946 and combination of I-BET and SGC0946 2.67
Functional interdependency of BRD4 and DOT1L in MLL leukaemia 2.67
Multiplexed engineering and analysis of endogenous enhancer activity in single cells: Mosaic-Seq of beta-globin locus (pooled infection) 2.66
Bioreactor-engineered cancer tissues mimic phenotypes, gene expression profiles and drug resistance mechanisms detectable in xenografts and clinical specimens. 2.64
RNA sequencing reveals levamisole target genes PTPRZ1 and MDK and their links to interferon pathway in human podocytes 2.63
Nucleotide stress induction of HEXIM1 suppresses melanoma by modulating cancer cell-specific gene transcription [RNA-Seq1] 2.48
Targetting super enhancer associated oncogenes in esophageal squamous cell carcinoma 2.46
Targetting super enhancer associated oncogenes in esophageal squamous cell carcinoma [RNA-seq] 2.46
RNA sequencing analysis of human podocytes reveals glucocorticoid regulated gene networks targeting non-immune pathways 2.44
Human Adult Sorted Live Cell Erythroblasts transduced with Sigma non-targeting shRNA negative control (SHC002V) with puromycin selection RNAseq 2.35
KDM1A confers invasive and metastatic attributes in lung adenocarcinoma by modulating a non-canonical Integrin ß3-KRAS signaling pathway 2.28
Gene expression profiling by RNA-seq in hTert-HME1 cell line treated with control or BRCA2 siRNAs and grown with or without EGF (epithelial growth factor) II 2.08
Analysis of transcriptional differences after IFN-beta (IFN-b) or IFN-lambda (IFN-l) treated human mid-gestation chorionic villus explants 1.9
Transcriptional analysis of ZIKV-infected Ifnar-/- and Ifnar+/- placentas and IFN-beta (IFN-b) or IFN-lambda (IFN-l) treated human mid-gestation chorionic villus explants 1.9
Impaired DNA damage metabolism promotes autoimmunity in TREX1 deficiency  1.86
Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival 1.85
The transition from proliferation to quiescence in glioblastoma stem-like cells requires Ca2+ signaling and mitochondria remodeling 1.84
CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops 1.81
Combined MEKi (GDC-0973) and WNT (G007-LK) treatment in APC and KRAS mutant HCT-15 cell line 1.6
Microenvironmental-derived Regulation of HIF-Signaling Drives Transcriptional Heterogeneity in Glioblastoma Multiforme 1.58
Programmable RNA N6-methyladenosine editing by CRISPR-Cas9 conjugates 1.57
Transcriptional profiling of growing and senescent WT and IL-1R-depleted IMR90 cells 1.54
Transcriptome analysis of the HepG2 cells expressing hepatic transcription factors 1.48
Cell cycle dynamics of human pluripotent stem cells primed for differentiation 1.44
Transcriptional Profiling of Werner Syndrome (WS) iPSC-derived MSC and the isogenic gene-edited controls 1.37
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression [ELL2 rescue] 1.3
JAG1 Mediated Notch Signaling Regulates Secretory Cell Differentiation of the Human Airway Epithelium 1.3
RNA-Seq analysis of proliferating 4N and 2N RPE1 cells derived from single cell clones following inhibition of Aurora B to induce polyploidization [tpo10] 1.26
Identification of miR-100 and miR-125b targets by AGO2 RIP-seq and RNA-seq after ectopic expression of miR-100 or miR-125b and evaluation of the TGFb expression signature in PANC-1 cells by RNA-seq 1.25
A systematic analysis of the time series gene expression in TGF-beta induced EMT by Next-generation sequencing 1.01
Smoking Dysregulates the Human Airway Basal Cell Transcriptome at COPD-linked Risk Locus 19q13.2 0.95
Role of OSGIN1 in Mediating Smoking-induced Autophagy in the Human Airway Epithelium [RNA-Seq] 0.93
Role of OSGIN1 in Mediating Smoking-induced Autophagy in the Human Airway Epithelium 0.93
Xeno-free and Chemically Defined Human System for Culturing Human Epidermal Keratinocytes 0.66
Concomitant BCORL1 and BRAF mutations in vemurafenib-resistant melanoma cells 0.56
DLX3 alters transcriptomic profile of adhesion, cell cycle, and cell death in Squamous Cell Carcinoma Cells 0.56
DLX3-dependent p53 signaling network controls keratinocyte cell cycle and squamous tumor growth 0.56
Host transcriptome analysis of Aspergillus fumigatus infection in Airway Epithelial Cells 0.55
Multiplexed engineering and analysis of endogenous enhancer activity in single cells: Mosaic-Seq of beta-globin locus (separate infection) 0.55
Xrn2 accelerates termination by RNA polymerase II, which is underpinned by CPSF73 activity 0.43
CD133hi, Notchhi, DP (double positive) and DN (double negative) in GBML8 and GBML20, both patient-derived glioblastoma tumorsphere cultures 0.29
Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify 0.27
RNA-Seq of SHEP TET21N cells upon Doxorubicin treatment 0.23
Zika virus infection reprograms global transcription of host cells to allow sustained infection 0.12
Long-term expandable SOX9+ chondrogenic ectomesenchymal cells from human pluripotent stem cells 0.02
HIV Reprograms Human Airway Basal Stem/Progenitor Cells to Acquire a Tissue Destructive Phenotype 0.01


Contact Us

For scientific and technical queries contact Butte Lab @UCSF


Cite GENEVA Tool

Manuscript in Preparation